Compare IDEXX Laboratories, Inc. (IDXX) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Atlassian Corporation PLC — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Atlassian Corporation PLC trades at $154.98 (market cap $39.10B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | TEAM | |
|---|---|---|
Market Cap | $46.22B | $39.10B |
Sector | Health | Technology |
52-Week High | $766.68 | $182.36 |
52-Week Low | $526.44 | $57.15 |
Enterprise Value | $47.12B | $39.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Atlassian (TEAM) trades at $155.15, up 2.16% with strong momentum following a 35% surge post-earnings. The stock shows bullish technical signals with moving averages supporting upward trends, though RSI indicates overbought conditions. Fundamentally, revenue growth remains robust at 28% YoY in Q4 2026, with cloud revenue accelerating to 31% and the company achieving its first full year of GAAP profitability. Analyst sentiment is overwhelmingly positive with 67% buy ratings and a $161.93 consensus target.
Outlook remains favorable with AI platform adoption and enterprise deal expansion driving growth, though valuation metrics appear stretched with EV/EBITDA at 184x. Key risks include competitive pressures in software and execution challenges in maintaining cloud momentum. The stock's proximity to 52-week highs suggests potential for consolidation near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
